. 2020 Mar 25;2020:19-0139. doi: 10.1530/EDM-19-0139
This work is licensed under a Table 3.
Clinical and laboratory characteristics of the patient before and after metreleptin and setmelanotide therapies.
| Before metreleptin | 1 year after metreleptin | Before setmelanotide | End of setmelanotide | |
|---|---|---|---|---|
| Age | 12 years and 10 months | 13 years and 10 months | 15 years and 10 months | 16 years and 2 months |
| Height (m) | 1.54 | 1.60 | 165 | 166 |
| Weight (kg) | 41.3 | 46.8 | 53.4 | 56 |
| BMI (kg/m2) | 17.4 | 18.3 | 19.6 | 20.4 |
| Waist (cm) | 74 | 77 | 85.2 | 83.6 |
| Blood Pressure (Sys:Dia mmHg) | 117:67 | 121:62 | 136:82 | 111:78 |
| Pulse (per min) | 86 | 71 | 82 | 87 |
| % Body Fat | 21.00 | 19.90 | 22.74 | 22.29 |
| FMR | 1.99 | 2.23 | 2.00 | 1.89 |
| % Liver Fat (PDFF) | 5.00 | 3.48 | 16.3 | 19.9 |
| Triglyceride (mg/dL; mmol/L) | 305 (3.45) | 303 (3.42) | 1601 (18.09) | 1590 (17.97) |
| Cholesterol (mg/dL; mmol/L) | 169 (4.37) | 142 (3.67) | 239 (6.18) | 199 (5.15) |
| HDL (mg/dL; mmol/L) | 29 (0.75) | 28 (0.72) | 25 (0.65) | 24 (0.62) |
| LDL (mg/dL; mmol/L) | 79 (2.04) | 53 (1.37) | 28 (0.72) | 32 (0/83) |
| Hemoglobin A1c (%; mmol/mol) | 5.8 (40) | 5.9 (41) | 9.7 (83) | 10.6 (92) |
| Daily total insulin dose (units) | None | None | 234 | 176 |
| Creatinine (mg/dL, mmol/L) | 0.44 (0.039) | 0.54 (0.048) | 0.56 (0.049) | 0.57 (0.050) |
| ALT (IU/L) | 73 | 31 | 34 | 50 |
| AST (IU/L) | 53 | 31 | 44 | 41 |
| ALP (IU/L) | 348 | 293 | 116 | 136 |
| Leptin (ng/mL)* | 7.4 | 271.7 | <0.6 | <0.6 |
*Leptin level measured via ELISA.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; FMR, fat mass ratio; GGTP, gamma-glutamyl transpeptidase; HDL, high density lipoprotein; LDL, low density lipoprotein; NA, not applicable; PDFF,: proton density fat fraction.